Array biopharma inc (ARRY)
CashFlow / TTM
Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Cash flows from operating activities
Net Income (Loss) Attributable to Parent

-126,115

-111,472

-134,163

-147,346

-124,490

-136,956

-126,204

-116,818

-112,240

-99,598

-100,461

-92,840

-80,560

422

15,975

9,369

-6,134

-89,373

-97,170

-85,257

-74,671

-71,332

-65,854

-61,942

-52,318

-38,893

-31,769

-23,581

-37,306

-40,638

-49,274

-56,324

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

2,142

2,167

2,192

2,236

2,269

2,235

2,170

2,068

1,750

1,641

1,531

1,529

2,204

2,756

3,299

3,702

3,706

3,958

4,279

4,506

4,576

4,425

4,307

4,350

4,561

4,724

4,888

5,076

7,115

7,302

7,460

7,616

0

0

0

Non-cash interest expense

5,914

5,614

5,732

6,252

6,843

7,424

7,486

7,223

6,967

6,708

6,530

6,375

6,223

6,078

5,946

5,799

5,654

5,510

5,385

5,258

5,109

4,893

4,716

4,476

0

0

0

-

-

-

6,005

6,377

0

0

0

Share-based compensation expense

24,232

20,630

18,336

19,107

16,605

14,776

13,635

9,965

8,764

7,679

7,437

7,283

8,100

8,209

8,399

7,809

6,377

5,535

4,531

4,331

4,144

3,895

3,623

3,449

3,104

2,757

2,579

2,351

2,190

2,483

2,797

3,328

0

0

0

Realized gain or loss on investments, net

36

35

35

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Impairment loss related to cost method investment

-

-

-

-

-

-

-

1,500

1,500

1,500

1,500

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing fees on notes payable

-

-

-

-

-

-

-

240

240

240

117

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of notes payable

3,164

2,864

3,564

3,299

4,900

3,500

0

2,600

-2,100

-800

-200

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash license revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,500

4,500

4,500

4,500

0

0

0

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-12,498

-7,725

17,777

805

11,651

-13,152

-7,337

-8,023

-18,414

10,260

20,434

32,995

48,805

34,698

14,218

7,592

4,397

-832

4,986

-4,166

869

4,018

-877

8,520

0

0

0

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

43,494

36,310

13,797

3,067

-2,041

-1,513

-4,543

-6,179

971

-466

1,404

4,352

2,410

2,977

798

1,260

703

1,274

3,172

1,961

126

66

1,618

746

1,429

1,287

-634

-1,044

-11,901

-1,711

-2,549

632

0

0

0

Accounts payable and other accrued expenses

978

1,345

8,697

5,716

4,371

5,129

3,635

-1,004

-7,793

-6,755

-2,164

3,931

8,274

2,403

1,684

-1,113

460

6,382

2,774

1,866

250

-1,029

-693

-1,324

2,036

-639

-1,018

1,084

-335

1,432

546

-1,173

0

0

0

Accrued outsourcing costs

5,025

14,234

-3,269

465

3,726

-1,752

11,979

12,248

7,386

8,572

7,895

1,738

8,286

6,293

3,950

7,362

6,900

6,832

7,359

4,464

2,976

2,847

1,902

182

-738

138

-139

146

1,167

43

607

341

0

0

0

Accrued compensation and benefits

6,099

7,333

5,009

5,390

2,908

1,383

2,031

1,539

724

-246

1,390

1,126

36

725

-655

-702

-544

-504

-609

-1,272

-452

316

856

1,951

2,012

339

1,664

1,099

-1,113

-4,854

-3,850

-3,582

0

0

0

Co-development liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,169

16,357

18,329

7,445

5,165

4,973

2,720

2,106

1,812

0

0

0

-

-

-

-

-

-

-

-

Deferred rent

-472

-460

-112

-33

-23

1,170

1,192

1,564

2,256

1,559

904

175

-801

-2,248

-2,734

-3,236

-3,709

-3,706

-3,685

-3,645

-3,604

-3,566

-3,527

-3,489

-3,450

-3,410

-5,030

-3,332

-8,060

-6,429

-3,142

-3,180

0

0

0

Deferred revenue

-5,425

-7,248

-17,495

-17,661

15,825

16,586

27,414

25,664

7,189

36,821

31,421

37,831

21,034

-1,072

3,957

1,584

3,398

-6,788

-11,567

-4,807

-12,528

-16,266

-22,955

-41,214

-43,261

-48,131

-56,119

-31,613

-33,259

-24,293

-6,083

-30,471

0

0

0

Other non-current liabilities

-565

168

122

207

572

192

195

184

120

34

47

109

20

-161

-202

-178

-119

117

77

4

-2

-135

-103

-106

0

0

0

-

-

-

-

197

0

0

0

Other liabilities and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Net cash used in operating activities

-116,055

-93,045

-136,539

-119,783

-73,847

-67,320

-42,793

-39,354

-64,123

-50,839

-65,491

-70,090

-89,893

-50,471

-6,228

-5,793

-766

-54,150

-89,339

-71,682

-63,527

-70,619

-66,809

-87,067

-82,962

-78,158

-68,443

-33,546

-35,358

-39,145

-31,521

-65,962

0

0

0

Cash flows from investing activities
Purchases of property and equipment

1,565

1,863

1,473

1,232

1,335

1,999

2,498

3,520

3,740

3,389

3,794

3,159

3,159

2,290

2,435

2,507

3,323

3,609

2,899

2,614

1,694

1,601

1,734

2,340

2,350

1,975

1,808

1,437

1,680

1,704

1,966

1,901

0

0

0

Proceeds from investment

35

35

35

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from investment

-

-

425,442

-

-

-

445,840

387,554

388,620

261,813

144,001

139,150

210,456

214,067

215,967

202,908

109,565

91,102

94,466

95,602

117,733

116,895

127,715

110,723

83,604

108,421

58,954

51,339

41,254

28,944

46,701

53,427

0

0

0

Purchases of marketable securities

421,534

363,337

309,330

252,797

188,919

324,356

328,480

332,429

320,942

173,253

196,082

208,336

203,707

227,767

178,848

143,616

139,490

108,013

107,655

100,698

102,609

94,162

87,977

96,701

77,478

59,153

45,602

34,055

42,877

81,463

113,649

129,423

0

0

0

Net cash used in investing activities

-17,375

22,868

-117,550

-191,037

-243,901

-205,212

-119,329

-58,116

-70,889

-91,949

48,287

66,027

-6,158

15,160

-35,804

-58,049

26,602

13,302

10,290

2,482

-16,818

-24,334

-41,472

-16,362

-8,476

-51,243

-15,160

-18,721

-57

50,815

64,982

74,095

0

0

0

Proceeds from exercise of stock options and shares issued under the employee stock purchase plan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net proceeds from the issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

75,000

50,155

44,810

90,966

75,555

0

0

0

-

-

-

-

6,060

0

0

0

Payments of Stock Issuance Costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

951

-

1,239

1,258

1,087

1,552

1,042

928

5,129

4,659

0

0

0

-

-

-

-

-

-

-

-

Net proceeds from notes payable at fair value

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of financing fees on notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from employee stock purchases and options exercised

15,101

7,359

20,475

20,775

18,320

15,438

3,509

2,344

2,270

1,623

1,626

2,032

2,941

5,074

5,012

4,398

3,793

2,165

2,322

3,693

3,998

3,436

3,180

2,120

1,812

1,744

1,477

1,169

0

0

0

-

-

-

-

Payment of note payable

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Proceeds from the modification of long-term debt, net

33,776

33,776

33,776

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment for debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

86

4,274

4,274

4,283

4,188

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

156,211

152,220

89,182

299,635

307,854

274,798

391,694

166,805

156,303

148,320

26,688

4,970

17,039

24,419

51,561

50,942

63,456

61,799

60,833

77,055

88,525

82,582

124,272

108,366

72,411

128,603

60,290

59,967

61,086

6,502

5,614

7,120

0

0

0

Net increase in cash and cash equivalents

-

0

-164,907

-

-

2,266

229,572

69,335

21,291

5,532

9,484

907

-79,012

-10,892

9,529

-12,900

89,292

20,951

-18,216

7,855

8,180

-12,371

15,991

4,937

-19,027

-798

-23,313

7,700

25,671

18,172

39,075

15,253

0

0

0

Supplemental disclosure of cash flow information
Cash paid for interest

5,416

5,078

5,088

4,026

4,322

4,304

4,345

4,386

4,438

4,485

4,475

4,466

4,460

4,451

4,450

4,450

4,445

4,445

4,346

4,349

3,621

5,228

4,953

6,564

6,920

6,925

6,932

7,008

7,288

7,929

8,567

9,105

0

0

0

Change in unrealized gain (loss) on marketable securities

922

567

-270

-385

-671

-626

-53

-83

-100

-13

-6

2

-9,784

-13,500

-14,505

3

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-